Search
ASCO data closing in on PD1 market
New ASCO 2016 data continues to support lower than consensus potential revenues, modest anti PD-L1 efficacy and more doubts over chemo combos
With PD-1 checkpoint inhibition clearly set to improve the landscape of cancer therapy for thousands of sufferers, we look at the upcoming 2016 ASCO abstracts and see further data supporting our lower forecasts, modest PD-L1 efficacy and further issues with the much vaunted chemo combinations. We continue to find that the global anti PD-1/PD-L1 market is worth an un‑risk adjusted $10.9bn a year, materially less than the optimistic (in our view) $20-$30bn forecasts in the market today
